It’s being expected that by 2028, the Next-Generation Sequencing Services market cap will hit $14.1 billion at a CAGR growth of about 20.4%.
The next-generation (NGS) services market has introduced several innovative advancements in NGS technology to promote usage in hospitals and clinical labs. Most current innovations in this field revolve around simplifying usage of seq-technology and making it more sophisticated. These major factors of the next generation sequencing services industry have driven the uptake of NGS services across several end users.
Conventional disease testing service providers have effectively broadened their portfolio with an increasing trend of seq-based genetic tests. In October 2014, ARUP Laboratories collaborated with the Children’s Hospital of Philadelphia (CHOP). The service provision for NGS-based HLA genotyping, including HLA Class I, Class II, initiated in November 2017.
With the growing trend of high throughput sequencing within the biotech and pharmaceutical industry, there is a significant need for more developments to improvise the speed and convenience of high throughput seq-platforms and simplify workflows. Moreover, companies are focusing on development of solutions to simplify the amplifications and purification of sample and starting input.
The global next-generation sequencing services market is segmented into several classifications including type outlook, workflow outlook, end-use outlook, regional outlook. Based on the type outlook the global next-generation sequencing (NGS) services market is categorized into Human Genome Sequencing, Single Cell Sequencing, Microbial Genome-based Sequencing, Gene Regulation Services, Small RNA Sequencing, ChIP Sequencing, Other Gene Regulation-based Services, Animal & Plant Sequencing, and Other Sequencing Services. Furthermore, on the basis of workflow outlook the next-generation sequencing (NGS) market is classified pre sequencing, sequencing, and data analysis. Based on the end-use outlook the global next generation sequencing (NGS) services universities & other research entities, hospitals & clinics, pharma & biotech entities, and others. Discussing the regional outlook, the global next-generation sequencing (NGS) market North America, U.S., Canada, Europe, Germany, U.K., Asia Pacific, China, Japan, Latin America, Brazil, and Middle East & Africa, South Africa.
Leading players of the global NGS services market include Illumina, Inc.; Eurofins Genomics; BGI; GENEWIZ Germany GmbH., Novogene Corporation, and others.
Next-Generation Sequencing Services Market Scope
Metrics | Details |
Base Year | 2022 |
Historic Data | 2018-2019 |
Forecast Period | 2022-2028 |
Study Period | 2018-2028 |
Forecast Unit | Value (USD) |
Revenue forecast in 2028 | $14.1 billion |
Growth Rate | CAGR of 20.4% during 2018-2028 |
Segment Covered | by Type, Technology, Regions |
Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
Key Players Profiled | BGI (China), Eurofins Scientific SE (Luxembourg), PerkinElmer, Inc. (U.S.), Macrogen Inc. (South Korea), GENEWIZ, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), Novogene Corporation (China), and GATC Biotech AG (Germany), |
Key Segmentation of the Global Next-Generation Sequencing (NGS) Services Market
NGS Service Type Outlook
- Human Genome Sequencing
- Single Cell Sequencing
- Microbial Genome-based Sequencing
- Gene Regulation Services
- Small RNA Sequencing
- ChIP Sequencing
- Other Gene Regulation-based Services
- Animal & Plant Sequencing
- Other Sequencing Services
NGS Services Workflow Outlook
- Pre Sequencing
- Sequencing
- Data Analysis
NGS Services End-use Outlook
- Universities & Other Research Entities
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
NGS Services Regional Outlook
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Middle East & Africa
- South Africa